105.21 +0.27 (0.26%)
After hours: 4:26PM EST
|Bid||104.97 x 800|
|Ask||104.98 x 800|
|Day's Range||104.93 - 105.75|
|52 Week Range||78.95 - 108.30|
|Beta (3Y Monthly)||0.84|
|PE Ratio (TTM)||19.70|
|Earnings Date||Feb 12, 2020 - Feb 17, 2020|
|Forward Dividend & Yield||2.12 (2.01%)|
|1y Target Est||108.69|
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $800 million aggregate principal amount of its 2.950% senior notes due 2030 under the Quest Diagnostics' shelf registration statement.
Moody's Investors Service ("Moody's") assigned a Baa2 rating to the proposed offering of senior unsecured notes of Quest Diagnostics Incorporated ("Quest"). There are no changes to Moody's existing ratings of Quest including the Baa2 senior unsecured long-term rating. Further, Quest has a long track record of maintaining modest financial leverage and generating stable cash flows, which Moody's expects will continue.
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
Today I will take a look at Quest Diagnostics Incorporated's (NYSE:DGX) most recent earnings update (30 September...
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SECAUCUS, N.J. , Nov. 20, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly ...
Other Company Research Demonstrates the Value of Diagnostic Insights in Early Cardiovascular Disease Detection in Clinical and Workplace Settings SECAUCUS, N.J. , Nov. 14, 2019 /PRNewswire/ -- A laboratory ...
SECAUCUS, N.J., Nov. 5, 2019 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced that it has achieved Gold status in the American Heart Association's 2019 Workplace Health Achievement Index, ranking the company's workplace health initiative among the best in the nation. 2019 marks the second year in a row that Quest has earned this distinction. The Index uses science-based best practices to evaluate the overall quality and comprehensiveness of workplace health programs.
Does the November share price for Quest Diagnostics Incorporated (NYSE:DGX) reflect what it's really worth? Today, we...
- Third quarter revenues of $1.96 billion , up 3.5% from 2018 - Third quarter reported diluted earnings per share from continuing operations ("EPS") of $1.56 , up 2.8% from 2018; and adjusted ...
NEW YORK, NY / ACCESSWIRE / October 22, 2019 / Quest Diagnostics, Inc. (NYSE: DGX ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on October 22, 2019 at 8:30 ...
Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 12 months is one of those periods, as the Russell 2000 […]
Moody's rating action reflects a base expected loss of 16.5% of the current pooled balance, compared to 11.3% at Moody's last review. Exceptions to this approach exist for the following disclosures, if applicable to jurisdiction: Ancillary Services, Disclosure to rated entity, Disclosure from rated entity.
Quest Diagnostics (DGX) is likely to have retained its two-pronged agenda to accelerate growth and drive operational excellence in the third quarter.
SECAUCUS, N.J., Oct. 16, 2019 /PRNewswire/ -- Most primary care physicians (62%) fear the opioid drug crisis will be traded for a new prescription drug crisis and nearly three quarters (72%) worry that chronic pain patients will turn to illicit drugs if they do not have access to prescription opioids, according to a new Health Trends™ report from Quest Diagnostics (DGX). Seventy percent of primary care physicians wish they had more training on how to taper their patients off opioids.
The long-anticipated offices were first approved in 2015, and had been under construction for the last two years.
This is the second of two stories that Investopedia is devoting to a report from Goldman Sachs recommending stocks with longterm stable profit growth.
Managenment believes that under Schechter's term with Paul and John's crucial support, LabCorp (LH) looks well-positioned to grow and thrive in times ahead.
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Quest...